Regenerative medicine in Fuchs' endothelial corneal dystrophy

The management of Fuchs' endothelial corneal dystrophy (FECD) has evolved rapidly since the introduction of endothelial keratoplasty (EK). In recent years, advances in our understanding of endothelial cell biology, in particular with respect to the regenerative capacity of endothelial cells, ha...

Full description

Bibliographic Details
Main Authors: Amy E Yuan, Roberto Pineda
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Taiwan Journal of Ophthalmology
Subjects:
Online Access:http://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=2;spage=122;epage=131;aulast=Yuan
_version_ 1819126885235294208
author Amy E Yuan
Roberto Pineda
author_facet Amy E Yuan
Roberto Pineda
author_sort Amy E Yuan
collection DOAJ
description The management of Fuchs' endothelial corneal dystrophy (FECD) has evolved rapidly since the introduction of endothelial keratoplasty (EK). In recent years, advances in our understanding of endothelial cell biology, in particular with respect to the regenerative capacity of endothelial cells, have opened the door to novel therapeutic options that stray from the traditional paradigm of allograft transplantation. We review the development of descemetorhexis without EK (DWEK) as a primary treatment for FECD and discuss the lessons learned to date about the mechanism of wound healing, surgical technique, patient selection, and refractive outcomes. Multiple randomized clinical trials are currently underway to evaluate the potential for pharmacological supplementation with rho-associated kinase inhibitors to increase the success rate of corneal clearance following DWEK. Biologic supplementation with intracameral endothelial cell injection and acellular Descemet's membrane transplantation are other avenues of adjuvant therapy. DWEK is a promising surgical option for management of a subset of FECD patients.
first_indexed 2024-12-22T08:03:08Z
format Article
id doaj.art-3948a21c08314068bb6b64787370d458
institution Directory Open Access Journal
issn 2211-5056
2211-5072
language English
last_indexed 2024-12-22T08:03:08Z
publishDate 2021-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Taiwan Journal of Ophthalmology
spelling doaj.art-3948a21c08314068bb6b64787370d4582022-12-21T18:33:12ZengWolters Kluwer Medknow PublicationsTaiwan Journal of Ophthalmology2211-50562211-50722021-01-0111212213110.4103/tjo.tjo_23_20Regenerative medicine in Fuchs' endothelial corneal dystrophyAmy E YuanRoberto PinedaThe management of Fuchs' endothelial corneal dystrophy (FECD) has evolved rapidly since the introduction of endothelial keratoplasty (EK). In recent years, advances in our understanding of endothelial cell biology, in particular with respect to the regenerative capacity of endothelial cells, have opened the door to novel therapeutic options that stray from the traditional paradigm of allograft transplantation. We review the development of descemetorhexis without EK (DWEK) as a primary treatment for FECD and discuss the lessons learned to date about the mechanism of wound healing, surgical technique, patient selection, and refractive outcomes. Multiple randomized clinical trials are currently underway to evaluate the potential for pharmacological supplementation with rho-associated kinase inhibitors to increase the success rate of corneal clearance following DWEK. Biologic supplementation with intracameral endothelial cell injection and acellular Descemet's membrane transplantation are other avenues of adjuvant therapy. DWEK is a promising surgical option for management of a subset of FECD patients.http://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=2;spage=122;epage=131;aulast=Yuandescemet's stripping onlydescemetorhexis without endothelial keratoplastyfuchs' endothelial corneal dystrophyregenerative medicinerho-associated kinase inhibitor
spellingShingle Amy E Yuan
Roberto Pineda
Regenerative medicine in Fuchs' endothelial corneal dystrophy
Taiwan Journal of Ophthalmology
descemet's stripping only
descemetorhexis without endothelial keratoplasty
fuchs' endothelial corneal dystrophy
regenerative medicine
rho-associated kinase inhibitor
title Regenerative medicine in Fuchs' endothelial corneal dystrophy
title_full Regenerative medicine in Fuchs' endothelial corneal dystrophy
title_fullStr Regenerative medicine in Fuchs' endothelial corneal dystrophy
title_full_unstemmed Regenerative medicine in Fuchs' endothelial corneal dystrophy
title_short Regenerative medicine in Fuchs' endothelial corneal dystrophy
title_sort regenerative medicine in fuchs endothelial corneal dystrophy
topic descemet's stripping only
descemetorhexis without endothelial keratoplasty
fuchs' endothelial corneal dystrophy
regenerative medicine
rho-associated kinase inhibitor
url http://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=2;spage=122;epage=131;aulast=Yuan
work_keys_str_mv AT amyeyuan regenerativemedicineinfuchsendothelialcornealdystrophy
AT robertopineda regenerativemedicineinfuchsendothelialcornealdystrophy